Hydrogen inhalation along with metformin cardioprotective against diabetic cardiomyopathy

A new study found that inhaling hydrogen reduces pyroptosis and fibrosis in diabetic cardiomyopathy (DCM) and that hydrogen may be paired with metformin to have a more robust cardioprotective impact in DCM. The findings of this study were published in the journal Free Radical Biology and Medicine.

DCM is a significant cardiovascular consequence of long-term chronic diabetes that is associated with an elevated risk of arrhythmia morbidity and heart failure. The role of hydrogen in the pathophysiology of DCM is yet unknown. Metformin is a well-known pharmacological medication for the treatment of diabetes; nevertheless, the drug's negative effects limit its use in large doses.

Hydrogen is a unique medicinal gas having anti-inflammatory, anti-oxidative, anti-allergic, anti-apoptotic, and energy metabolism-boosting effects. Hydrogen therapy has been shown to be useful in treating myocardial ischemia, infarction, and ischemia-reperfusion damage. 

For more information check out the full story on the link below:   

Hydrogen Inhalation With Metformin Cardioprotective Against Diabetic Cardiomyopathy